Log In
Print this Print this

Enhanced TCR therapy for MM

  Manage Alerts
Collapse Summary General Information
Company Adaptimmune Therapeutics plc
DescriptionT cells genetically modified to express T cell receptors (TCR) targeting specific cancer antigens
Molecular Target Melanoma-associated antigen A3 (MAGEA3) ; Cancer/testis antigen 1B (CTAG1B) (NY-ESO-1)
Mechanism of Action 
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today